Neurostimulation can reduce seizures in some people whose epilepsy does not respond well to medicines, but it does not usually cure epilepsy. The main options are vagus nerve stimulation (VNS), responsive neurostimulation (RNS), and deep brain stimulation (DBS). Studies show meaningful seizure reductions for many patients, sometimes improving over years. Results differ by device and person, and the evidence does not prove that one approach is best for everyone.
What does the research show about neurostimulation?
Neurostimulation uses electrical signals to change activity in the nervous system and help reduce seizures. It is generally considered for drug-resistant epilepsy, which means seizures continue despite trials of appropriate antiseizure medicines. These devices are usually added to medication rather than used as replacements for it.
Research supports all three main approaches, but the strength and type of evidence differ. Clinical trials have tested whether stimulation reduces seizures, while longer follow-up studies have examined whether benefits continue over several years. The findings are encouraging, particularly for people whose seizures remain difficult to control, but they do not establish that neurostimulation will work for everyone.
How do researchers measure whether neurostimulation works?
Studies commonly measure the percentage reduction in seizure frequency compared with the period before treatment. They may also report the responder rate, which is the proportion of participants who experience at least a 50% reduction in seizures. Some studies examine seizure severity, quality of life, and periods without seizures as additional outcomes.
These measures describe different kinds of benefit. A person whose seizures become half as frequent may still have seizures, while someone who has a period without seizures may experience them again later. A reduction in seizure frequency is therefore not the same as a cure.
Study design also matters. A randomized, controlled trial can help determine whether a treatment has an effect beyond the changes that might occur without active stimulation. Longer follow-up studies provide information about durability and safety, but they may have no untreated comparison group, and medication changes or device adjustments can affect the results.
What is the evidence for vagus nerve stimulation (VNS)?
Vagus nerve stimulation uses a small implanted device, usually placed under the skin of the upper chest, with a wire connected to the vagus nerve in the neck. The device sends regular electrical pulses that affect brain activity. Some newer systems can also deliver additional stimulation when they detect a rapid rise in heart rate, and a handheld magnet may allow an extra pulse in certain situations.
The Epilepsy Foundation's overview of VNS describes it as an add-on treatment for drug-resistant seizures. Its patient information cites seizure reductions of approximately 28% after three months and 58% after four years. These figures come from different follow-up points and should not be interpreted as a guaranteed improvement for an individual.
Evidence suggests that the effect of VNS may increase gradually rather than appearing fully at the start of treatment. Some people also report less severe seizures or faster recovery afterward. However, VNS does not usually eliminate seizures completely, and its results vary from person to person.
VNS can be considered when epilepsy surgery to remove the seizure-producing area is not suitable, has not worked, or is not an option the person wishes to pursue. It is used in adults and children; in the United States, the device indication described by the Epilepsy Foundation includes children aged four years and older. Eligibility and approved uses may differ by country.
How strong is the evidence for responsive neurostimulation (RNS)?
Responsive neurostimulation works differently from VNS. Electrodes are placed at one or two identified areas where seizures begin, and an implanted device continuously monitors brain activity. When it detects patterns associated with a seizure, it delivers brief electrical pulses. The system can also record brain activity, which may help an epilepsy specialist assess seizure patterns over time.
The Epilepsy Foundation's RNS guidance describes this treatment as an option for certain people with drug-resistant focal seizures when removing the seizure-producing area is not possible or has not worked. In the United States, the device is indicated for adults aged 18 years and older and is used alongside antiseizure medication.
One important source of long-term evidence is a nine-year prospective study of brain-responsive neurostimulation. According to the US National Library of Medicine's PubMed record, the median reduction in seizure frequency reached 75% at nine years, and 73% of participants met the study's responder definition. Of the 256 people treated in the initial trials, 47 experienced at least one year without seizures during the study period.
These findings suggest that RNS can provide lasting seizure reduction for some people, with benefits that may increase over time. However, the long-term phase was open-label, meaning participants and clinicians knew the treatment was being given. The results are valuable evidence of sustained outcomes, but they do not provide a direct comparison with an untreated group over the full nine years. Extended seizure-free periods also do not establish permanent seizure freedom.
What does the evidence say about deep brain stimulation (DBS)?
Deep brain stimulation involves surgically placing electrodes in a selected brain structure. For epilepsy, one established approach targets the anterior nucleus of the thalamus, a region involved in brain networks associated with seizures. The device delivers electrical stimulation according to programmed settings rather than waiting to detect an individual seizure before responding.
The Epilepsy Foundation's guidance on DBS describes it as an option for certain adults with drug-resistant focal seizures when medicines alone are not effective and removal of the seizure focus is not a suitable solution. In the United States, the epilepsy indication described by the Foundation applies to people aged 18 years and older. DBS is used together with antiseizure medication.
Evidence for DBS includes the SANTÉ clinical trial and its long-term follow-up. The US National Library of Medicine's PubMed record for the SANTÉ study reports a median seizure-frequency reduction of 75% from baseline at seven years. The follow-up included people treated for at least ten years, although not all participants remained under observation for the entire period.
The long-term findings support the potential for sustained benefit from DBS. They should still be interpreted in context: after the initial blinded trial phase, treatment settings and medications could be changed, and the long-term results did not come from a continuing comparison with an untreated group. As with other neurostimulation approaches, improvement in seizure frequency does not necessarily mean that seizures will stop completely.
Can the results of VNS, RNS, and DBS be compared directly?
Not reliably from the headline percentages alone. The studies have enrolled different groups of people, targeted different brain pathways, and used different follow-up periods and research designs. The percentage reduction reported for one device may therefore not predict how it would perform in a person who is eligible for another device.
RNS is designed to detect abnormal activity at identified seizure-producing areas and respond with stimulation. DBS delivers stimulation to a deeper brain structure according to programmed settings, while VNS stimulates the vagus nerve in the neck. These differences affect which people may be considered for each approach and what type of information clinicians can obtain from a device.
The available evidence supports neurostimulation as a way to reduce seizure burden in selected people with drug-resistant epilepsy. It does not establish a single best device for all patients, and comparisons should account for seizure type, medical history, the location and number of seizure-producing areas, the study population, and the risks of implantation.
What are the risks and limitations of neurostimulation?
All implanted neurostimulation systems require a procedure and ongoing follow-up. Potential concerns include complications related to surgery, problems with the implanted device, and unwanted effects from stimulation. The type and likelihood of these effects vary by procedure and by the person's health and treatment needs.
With VNS, stimulation can cause a hoarse voice or other throat sensations. Settings can sometimes be adjusted to improve tolerance. RNS and DBS require electrodes to be placed in or on the brain, so the specialist team will discuss the procedure and its specific risks before treatment. Device programming, routine reviews, and decisions about battery or device maintenance are also part of ongoing care.
Another limitation is that neurostimulation often reduces rather than eliminates seizures. It may take time to adjust the device and assess its effect. Antiseizure medicines are usually continued, and any change to medication should be discussed with the treating clinician rather than made independently.
Who may benefit from neurostimulation?
Neurostimulation may be considered when seizures continue despite appropriate medication trials and a person needs additional treatment. An epilepsy specialist can assess whether a device is appropriate and whether epilepsy surgery or another treatment should also be considered. Evaluation may include a detailed review of seizure history, brain imaging, electroencephalogram testing, and tests to identify where seizures begin.
Device selection depends on the seizure pattern, whether the seizure-producing area can be identified safely, previous treatments, other health conditions, and the person's preferences. Age and local regulatory approvals matter as well: the US indications described by the Epilepsy Foundation include VNS from age four, while RNS and epilepsy DBS are indicated for adults aged 18 years and older.
For someone considering treatment, a useful discussion with an epilepsy specialist covers the likely goal of therapy, the evidence for the proposed device, possible risks, how success will be measured, and what follow-up will involve. The most realistic goal may be fewer or less severe seizures, improved recovery, and a better quality of life rather than complete seizure freedom.